Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5464714- Camlipixant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | In sequence 1, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 under fasting condition (Treatment A), followed by single dose of GSK5464714 in fed condition (Treatment B). There will be a washout period of minimum 7 days between each period. |
| Sequence 2 | EXPERIMENTAL | In sequence 2, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 in fed condition (Treatment B), followed by single dose of GSK5464714 under fasting condition (Treatment A). There will be a washout period of minimum 7 days between each period. |
| Name | Type | Description |
|---|---|---|
| GSK5464714- Camlipixant | DRUG | GSK5464714- Camlipixant will be administered |
Inclusion Criteria: * Participants who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, clinical laboratory tests, vital sign measurements, and 12-lead ECGs including the following: * Seat...
GSK5464714-Camlipixant is an investigational small molecule being developed for the treatment of cough. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in healthy participants to evaluate its effects, with a focus on respiratory conditions.
GSK5464714-Camlipixant is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
GSK5464714-Camlipixant is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied in early-stage trials to assess its safety, tolerability, and how it is processed by the body.
GSK5464714-Camlipixant has one completed Phase 1 clinical trial registered under NCT06497517. This study, titled 'A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants,' enrolled 14 participants in the United States and evaluated the drug's concentrations after food intake.
Yes, GSK5464714-Camlipixant is also known as Camlipixant. The drug is referred to by both names in clinical and research contexts. It is a small molecule being developed for cough and is currently in Phase 1 clinical trials.